ClinicalTrials.gg
CompletedNCT06771115Updated Sep 29, 2026Results posted

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

A Phase 2 interventional study of Placebo and VTX3232 30 mg in Obesity, sponsored by Zomagen Biosciences Ltd.. Completed at 14 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Zomagen Biosciences Ltd. (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

Updated Sep 29, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
76th of 117
175 · median 267
Started
2025
with 27 others
Phase 2
22 of 118
5 open now
Registered
65th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 76th largest by enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 22 in phase 2, and was the 65th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • NLRP3 Inhibitor
  • VTX3232
  • Zomagen
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are male or female ≥ 18 years up to ≤ 80 years of age.
  • Ability to comply with study requirements.
  • ≥ 30.0 to ≤ 42.0 kg/m2 at screening.
  • Stable body weight (± 5%) for at least 3 months prior to screening.
  • hs-CRP ≥ 2 mg/L at screening.
  • Hypertension or hyperlipidemia which are known to be associated with increased risk of cardiovascular events, if present, must be controlled with stable dose/therapy.
  • History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion criteria

Exclusion Criteria:

  • Obesity induced by endocrinologic disorders, or diagnosed genetic or syndromic forms of obesity
  • Have any prior diagnosis of diabetes mellitus
  • Current participation (or within the last 3 months) in an organized weight reduction program.
  • History or presence of gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility, have undergone prior surgical treatment for obesity (e.g., gastric bypass [bariatric] surgery or restrictive bariatric surgery), or have an endoscopic and/or device-based therapy for obesity.
  • Clinically relevant medical condition(s) that put the participant at risk or will make implementation of the protocol or interpretation of the study difficult.
  • Use of any medication (e.g., GLP-1 agonists), nutritional supplement, or over the counter product for weight loss within the previous 6 months or during study participation, unless administered as a part of assigned study treatment in this study.
  • Receipt of the following medications:

    1. Any biologic or targeted therapy within 90 days prior to Day 1.
    2. Use of anti-inflammatory medications within 30 days prior to Day 1
    3. Colchicine within 30 days prior to Day 1.
    4. Glucose-lowering agent(s) administered for conditions other than diabetes within 90 days before screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo orally once daily for 12 weeks and were followed for 30 days after the last dose.

    Drug: Placebo

  • Experimental
    VTX3232 30 mg

    Participants received VTX3232 30 milligrams (mg) orally once daily for 12 weeks and were followed for 30 days after the last dose.

    Drug: VTX3232 30 mg

  • Active comparator
    Placebo + Semaglutide

    Participants received placebo orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose.

    Drug: Placebo in combination with semaglutide

  • Experimental
    VTX3232 30 mg + Semaglutide

    Participants received VTX3232 30 mg orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose.

    Drug: VTX3232 30 mg in combination with semaglutide

Interventions

  • DrugPlacebo

    Placebo

  • DrugVTX3232 30 mg

    VTX3232 30 mg

  • DrugPlacebo in combination with semaglutide

    Placebo in combination with semaglutide

  • DrugVTX3232 30 mg in combination with semaglutide

    Drug page: Semaglutide

    VTX3232 30 mg in combination with semaglutide

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)

    A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment.

    Time frame: From the first dose of study treatment to Week 16

Secondary outcomes

  1. Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level

    Time frame: From baseline to Week 12

07

Results

Posted Sep 29, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + Semaglutide
Started43444345
Received at least one dose of the study drug43444345
Completed37344038
Not completed61037
Withdrew: Lost to follow-up2524
Withdrew: Withdrawal by subject2401
Withdrew: Adverse event2112

Outcome measures

PrimaryNumber of Participants With Any Treatment Emergent Adverse Events (TEAEs)

A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment.

Time frame:
From the first dose of study treatment to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + Semaglutide
Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)21202425
SecondaryPercent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level
Time frame:
From baseline to Week 12
Reported as:
Median · Percent change
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level
Percent changePlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + Semaglutide
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (Hs-CRP) Level2.98 (-30.56 to 40.82)-63.77 (-83.45 to -20.00)-28.11 (-48.28 to 3.13)-75.00 (-91.67 to -25.00)
Statistical analysis
  • Placebo vs VTX3232 30 mg · Wilcoxon (Mann-Whitney) · p = <0.0001 · Hodges-lehmann estimate: -56.18 · 95% CI -80.77 to -34.24
  • Placebo vs Placebo + Semaglutide · Wilcoxon (Mann-Whitney) · p = 0.0128 · Hodges-lehmann estimate: -24.67 · 95% CI -48.41 to -6.23
  • Placebo vs VTX3232 30 mg + Semaglutide · Wilcoxon (Mann-Whitney) · p = <0.0001 · Hodges-lehmann estimate: -65.45 · 95% CI -86.41 to -47.59
  • Placebo + Semaglutide vs VTX3232 30 mg + Semaglutide · Wilcoxon (Mann-Whitney) · p = 0.0002 · Hodges-lehmann estimate: -41.26 · 95% CI -57.93 to -23.33

Adverse events

Collected over From baseline to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/43 (0%)0/43 (0%)13/43 (30.2%)
VTX3232 30 mg0/44 (0%)1/44 (2.3%)10/44 (22.7%)
Placebo + Semaglutide0/43 (0%)0/43 (0%)20/43 (46.5%)
VTX3232 30 mg + Semaglutide0/45 (0%)0/45 (0%)22/45 (48.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + Semaglutide
Major depressionPsychiatric disorders0/431/440/430/45
Most frequent other events
Most frequent other events
EventPlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + Semaglutide
NauseaGastrointestinal disorders2/432/448/4310/45
ConstipationGastrointestinal disorders3/432/446/436/45
Early satietyGeneral disorders1/432/446/435/45
Decreased appetiteMetabolism and nutrition disorders2/431/446/436/45
Gastrooesophageal reflux diseaseGastrointestinal disorders0/430/443/435/45
FatigueGeneral disorders2/431/444/435/45
DiarrhoeaGastrointestinal disorders3/432/443/434/45
VomitingGastrointestinal disorders0/431/443/431/45
HeadacheNervous system disorders3/432/442/432/45

Baseline characteristics

All randomized participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)PlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + SemaglutideTotal
Mean47.0 ± 13.4945.9 ± 13.4547.7 ± 13.4449.7 ± 14.6747.6 ± 13.74
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + SemaglutideTotal
Female33343435136
Male101091039
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + SemaglutideTotal
Hispanic or Latino12991545
Not Hispanic or Latino31353430130
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + SemaglutideTotal
American Indian or Alaska Native10214
Asian21003
Native Hawaiian or Other Pacific Islander00000
Black or African American1111111548
White29313029119
More than one race01001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)PlaceboVTX3232 30 mgPlacebo + SemaglutideVTX3232 30 mg + SemaglutideTotal
United States43444345175
08

Study locations

14 sites
  • 840005
    Birmingham, Alabama 35235, United States
  • 840003
    Lake Forest, California 92630, United States
  • 840011
    Long Beach, California 90815, United States
  • 840001
    Largo, Florida 33761, United States
  • 840012
    Ocoee, Florida 34761, United States
  • 840016
    Port Orange, Florida 32127, United States
  • 840014
    Newton, Kansas 67114, United States
  • 840015
    Marrero, Louisiana 70072, United States
  • 840017
    Marrero, Louisiana 70072, United States
  • 840002
    Austin, Texas 78705, United States
  • 840006
    Dallas, Texas 75230, United States
  • 840013
    San Antonio, Texas 78229, United States
  • 840018
    San Antonio, Texas 78229, United States
  • 840010
    Waco, Texas 76710, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Sep 2025, 8 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 13, 2025
StartActual
Jan 7, 2025
Primary completionActual
Sep 10, 2025
CompletionActual
Sep 10, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Enrollment
176→175
Sep 29, 2026
Interventions
Changed VTX3232 Dose A in combination with semaglutide→VTX3232 30 mg in combination with semaglutide. Added Drug: VTX3232 30 mg; removed Drug: VTX3232 Dose A. Arms added: VTX3232 30 mg·Placebo + Semaglutide·VTX3232 30 mg + Semaglutide; arms removed: VTX3232 Dose A·VTX3232 Dose A in combination with semaglutide·Placebo in combination with semaglutide
Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completionNow Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 of treatment period through study completion, up to 16 weeks → From the first dose of study treatment to Week 16
Sep 29, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPercent Change from baselineFrom Baseline to Week 12 in hsHigh-Sensitivity C-Reactive Protein (Hs-CRP level) LevelTime frame: Day 1 of treatment period to week 12 of treatment period → From baseline to Week 12
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Enrollment 176→175
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completionNow Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 of treatment period through study completion, up to 16 weeks → From the first dose of study treatment to Week 16
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPercent Change from baselineFrom Baseline to Week 12 in hsHigh-Sensitivity C-Reactive Protein (Hs-CRP level) LevelTime frame: Day 1 of treatment period to week 12 of treatment period → From baseline to Week 12
    Interventions Changed VTX3232 Dose A in combination with semaglutide→VTX3232 30 mg in combination with semaglutide. Added Drug: VTX3232 30 mg; removed Drug: VTX3232 Dose A. Arms added: VTX3232 30 mg·Placebo + Semaglutide·VTX3232 30 mg + Semaglutide; arms removed: VTX3232 Dose A·VTX3232 Dose A in combination with semaglutide·Placebo in combination with semaglutide
    + 4 other changes: identifiers, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06771115
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Jan 7, 2025
Primary completion
Sep 10, 2025
Completion
Sep 10, 2025
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Snehal Naik, PhD
study director · Zomagen Biosciences Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion